| Literature DB >> 31408152 |
Ulrike G Seeberger1, Joseph J Valadez1.
Abstract
High quality of care (QoC) for antiretroviral treatment (ART) is essential to prevent treatment failure. Uganda, as many sub-Saharan African countries, increased access to ART by decentralizing provision to districts. However, little is known whether this rapid scale-up maintained high-quality clinical services. We assess the quality of ART in the Acholi and Lango sub-regions of northern Uganda to identify whether the technical quality of critical ART sub-system needs improvement. We conducted a randomized cross-sectional survey among health facilities (HF) in Acholi (n = 11) and Lango (n = 10). Applying lot quality assurance sampling principles with a rapid health facility assessment tool, we assessed ART services vis-à-vis national treatment guidelines using 37 indicators. We interviewed health workers (n = 21) using structured questionnaires, directly observed clinical consultations (n = 126) and assessed HF infrastructure, human resources, medical supplies and patient records in each health facility (n = 21). The district QoC performance standard was 80% of HF had to comply with each guideline. Neither sub-region complied with treatment guidelines. No HF displayed adequate: patient monitoring, physical examination, training, supervision and regular monitoring of patients' immunology. The full range of first and second line antiretroviral (ARV) medication was not available in Acholi while Lango had sufficient stocks. Clinicians dispensed available ARVs without benefit of physical examination or immunological monitoring. Patients reported compliance with drug use (>80%). Patients' knowledge of preventing HIV/AIDS transmission concentrated on condom use; otherwise it was poor. The poor ART QoC in northern Uganda raises major questions about ART quality although ARVs were dispensed. Poor clinical care renders patients' reports of treatment compliance as insufficient evidence that it takes place. Further studies need to test patients' immunological status and QoC in more regions of Uganda and elsewhere in sub-Saharan Africa to identify topical and geographical areas which are priorities for improving HIV care.Entities:
Keywords: Antiretroviral therapy; HIV/AIDS treatment; Uganda; direct observation; quality of care
Mesh:
Substances:
Year: 2019 PMID: 31408152 PMCID: PMC6794567 DOI: 10.1093/heapol/czz074
Source DB: PubMed Journal: Health Policy Plan ISSN: 0268-1080 Impact factor: 3.344
Sample size, decision rule and classification errors for Acholi, Lango and northern Uganda
| Sub-region | No. eligible HF (No.) | pU | pL | Sample Size ( | Decision Rule ( | α error | β error |
|---|---|---|---|---|---|---|---|
| Acholi (original sample) | 20 | 0.8 | 0.5 | 10 | 7 | 0.043 | 0.089 |
| Acholi (additional facility added) | 20 | 0.8 | 0.5 | 11 | 8 | 0.068 | 0.035 |
| Lango | 21 | 0.8 | 0.5 | 10 | 7 | 0.049 | 0.095 |
In Acholi, we included one additional HF as a contingency in case of locating an inaccessible HF the resulting data were included in the analysis (see Acholi—additional facility added).
HF, health facilities.
Health facility classifications for input, performance, outcome and patient management indicators or antiretroviral therapy provision
| No. | Indicator label | Tool | Acholi ( | Lango ( |
|---|---|---|---|---|
|
| ||||
| 1a | Pre-service training | HWI | 2 | 5 |
| 1b | In-service training | HWI | 0 | 0 |
| 2 | Supervision | HWI | 1 | 2 |
| 3 | Laboratory supply (on site or referral system in place) | HFC | 10 | 8 |
| 4 | Equipment | HFC | 6 | 4 |
| 5ARV1 | ARV availability first line (all essential combinations available) | HFC | 6 | 7 |
| 5ARV2 | ARV availability second line (all essential combinations available) | HFC | 7 | 10 |
| 5TB | TB drug availability (all essential drugs available) | HFC | 4 | 2 |
| 5OPP | Anti-opportunistic drug availability (all essential drugs available) | HFC | 4 | 3 |
| 5FP | Family planning availability | HFC | 5 | 6 |
| 6ARV | Access to ARV (prescribed drugs available) | PI | 11 | 10 |
| 6OPP | Access to anti-opportunistic infection drugs (prescribed drugs available) | PI | 11 | 10 |
| 6Oth | Access to other medication (prescribed drugs available) | PI | 9 | 5 |
|
| ||||
| 7a | History taking: current well-being | Obs | 11 | 9 |
| 7b | History taking: hospitalization, changes | Obs | 4 | 4 |
| 7c | History taking: TB screen | Obs | 5 | 7 |
| 7d | History taking: symptom checklist | Obs | 0 | 0 |
| 8 | Physical examination | Obs | 0 | 0 |
| 9a | Treatment: consistent with HW diagnosis | Obs | 9 | 5 |
| 9b | Treatment: consistent with history and examination | Obs | 3 | 1 |
| 10a | Counselling: adherence strategies | Obs | 7 | 6 |
| 10b | Counselling: transmission of HIV | Obs | 3 | 0 |
| 10c | Counselling: family testing | Obs | 2 | 0 |
| 10d | Counselling: medication use | Obs | 8 | 5 |
|
| ||||
| 11a | Patient perception: history | PI | 10 | 9 |
| 11b | Patient perception: examination | PI | 6 | 4 |
| 12 | Patient knowledge: medication | PI | 11 | 10 |
| 13 | Patient’s adherence to medication | PI | 10 | 8 |
| 14 | Disclosure of the status to partner | PI | 11 | 9 |
| 15 | Family testing for HIV | PI | 10 | 6 |
| 16 | Patient knowledge: HIV | PI | 0 | 0 |
|
| ||||
| 17 | CD4-monitoring (last CD4-count not older than 9 months) | PR | 2 | 1 |
| 18 | ART Initiation | PR | 8 | 5 |
| 19a | ART documentation: TB screen | PR | 11 | 9 |
| 19b | ART documentation: treatment regimen | PR | 11 | 10 |
| 19c | ART documentation: counselling | PR | 2 | 0 |
| 20 | Follow-up | PR | 9 | 8 |
= failure of a sub-region for that indicator, = success of a sub-region for that indicator. The sub-regions were appraised according to the upper and lower threshold (pU = 80%, pL = 50%, Acholi: N = 20, n = 11, d = 8; Lango: N = 21, n = 10, d = 7).
HWI, health worker interview; PI, patient interview; Obs, observation of the clinical visit; PR, patients’ records.